Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with the ...
After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback